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a-MSH signals by binding to the melanocortin-1 receptor (MC-1R) and elevating cyclic AMP in several different
cells. The anti-inﬂammatory properties of this peptide are also believed to be cyclic AMP dependent. The carboxyl
terminal tripeptides of a-MSH (KPV / KP-D-V) are the smallest minimal sequences reported to prevent inﬂammation
but it is not known if they operate via MC-1R or cyclic AMP. The aim of this study was to examine the intracellular
signalling of key MSH and ACTH peptides in human keratinotocytes. No elevation in cyclic AMP was detected in
either HaCaT or normal human keratinocytes in response to a-MSH, KPV or ACTH peptides. Rapid and acute
intracellular calcium, however, were observed in HaCaT keratinocytes in response to a-MSH (1015–107 M), KPV
(1015–107 M), KP-D-V (1015107 M) and ACTH (1015–107 M), but only in the presence of PIA, an adenosine
agonist that inhibits the cyclic AMP pathway. Normal keratinocytes responded to all the above peptides but in
addition responded to ACTH 1–17 (1013–107 M) in contrast to the HaCaT keratinocytes. Stable transfection of
Chinese hamster ovary cells with the MC-1 receptor showed that a-MSH and the KPV peptides elevated intracellular
calcium.
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a-Melanocyte-stimulating hormone (a-MSH) is produced in
a number of vertebrate tissues including the intermediate
lobe of the pituitary, gut, and skin (Eberle, 1988). It is derived
by processing of a proopiomelanocortin (POMC) precursor
molecule, and has a number of reported biological func-
tions. It is principally known for stimulating eumelanogenic
pigmentation in skin tissue (Thody, 1995; Eberle, 2000), has
been reported to influence sexual behavior in rodents
(Jordan and Jackson, 1998) and has a potent immunomo-
dulatory function of inhibiting fever and inflammation (Hiltz
et al, 1991; Lipton et al, 1991; Watanabe et al, 1993; Lipton
and Catania, 1997). Recent evidence also suggests that
adrenocorticotropin hormone (ACTH) and smaller ACTH
fragments are produced in extra pituitary tissues, including
skin (Chakraborty et al, 1996; Wakamatsu et al, 1997;
Tsatmali et al, 1999; Slominski et al, 2000a). ACTH is a 39-
amino acid peptide also derived from POMC by the action
of prohormone convertase-1 (PC-1). Further proteolysis of
ACTH by PC-2 generates a-MSH (Benjannet et al, 1991).
ACTH has a major role of acting on the adrenal cortex,
regulating glucocorticoid production; however, an immuno-
modulatory role in the skin is also reported (Slominski et al,
2000b).
Short MSH peptide derivatives are also reported to
possess anti-inflammatory biology. The most notable of
these is the carboxyl-terminal tripeptide MSH 11–13 (L-Lys-
L-Pro-L-Val; KPV) and its synthetic stereochemical analog
MSH 11–13 (L-Lys-L-Pro-D-Val; KP-D-V) reported to be the
minimal sequence necessary for preventing inflammation in
vivo (Lipton, 1997). We have previously shown that KPV and
KP-D-V inhibit the tumor necrosis factor-a (TNF-a) activation
of nuclear factor kB (NF-kB), glutathione peroxidase (GPx),
and peroxide elevation (Haycock et al, 2000; Moustafa et al,
2002) in keratinocyte and melanoma cells. But it is not
known exactly how these short peptides signal. It is known
that a-MSH signals by the melanocortin-1 G-protein linked
receptor (melanocortin-1 receptor (MC-1R)) and that five
melanocortin receptors have been cloned to date (Chhajlani
and Wikberg, 1992; Mountjoy et al, 1992). The most
commonly expressed receptor in skin tissue is MC-1R,
found on keratinocytes (Chakraborty et al, 1996; Jiang et al,
1996), melanocytes (Mountjoy et al, 1992; Thody et al, 1993;
Jiang et al, 1996), and fibroblasts (Bo¨hm et al, 1999).
Expression is also reported for endothelial cells (Hartmeyer
et al, 1997) and monocytes (Bhardwaj et al, 1997). ACTH
signals through MC-2R and is expressed predominantly on
adrenal corticotropic cells. Expression is also reported for
keratinocytes (Moustafa et al, 2002) therefore raising
Abbreviations: ACTH, adrenocorticotropin hormone; cAMP, cyclic
adenosine monophosphate; KP-D-V, L-Lys-L-Pro-D-Val; KPV, L-Lys-
L-Pro-L-Val; MC-1R, melanocortin-1 receptor; a-MSH, a-melano-
cyte stimulating hormone; NF-kB, nuclear factor-kB; PIA, N6-(L-2-
phenyl isopropyl) adenosine; TNF-a, tumor necrosis factor-a
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questions on the role of ACTH/MC-2R signalling in the skin.
Of particular interest are reports where peptides such as
ACTH1–17 have been isolated in human skin in relatively
high abundance (Wakamatsu et al, 1997) and have a very
high affinity for MC-1R (Tsatmali et al, 1999).
Melanocortin receptors typically signal via elevation of
cyclic adenosine monophosphate (cAMP) (Eberle, 1988).
The anti-inflammatory action of a-MSH appears to be
consistent with this, as use of receptor-independent cAMP
elevating agents (e.g., forskolin/isobutylmethylxanthine) can
mimic the a-MSH biology. a-MSH is also reported to act via
the p38 MAP kinase pathway promoting melanogenesis
and inhibiting growth in melanoma cells (Smalley and Eisen,
2000) and also activation of the STAT1 transcription factor
(Buggy, 1998). We have previously reported that a-MSH can
cause activation of protein kinase C (PKC) in melanoma
cells in vitro (Buffey et al, 1992) and can also induce acute
intracellular calcium release (MacNeil et al, 1990). As the
signalling mechanism of key MSH/ACTH peptides in skin
cells is incomplete the objective of this study was to
investigate whether human keratinocytes could respond to
a-MSH, the MSH 11–13 tripeptides (KPV and KP-D-V), and
the ACTH peptides (ACTH 1–39 and ACTH 1–17) with
elevation of cAMP or intracellular calcium, and in B16F10C1
mouse melanoma cells with activation of dopa oxidase. We
also investigated the mechanism of signalling in Chinese
hamster ovary cells stably transfected with the MC-1R
versus wild-type, and investigated the functional behavior of
elevating intracellular calcium on TNF-a activation of NF-kB
in keratinocytes.
Results
Elevation of intracellular calcium in keratinocytes Acute
intracellular calcium responses to the peptides ACTH,
ACTH 1–17, a-MSH, KPV, and KP-D-V were measured in
normal human keratinocytes and HaCaT keratinocytes,
using cell-averaged fluorimetry. In both cell types, the
addition of peptide alone did not cause an increase
in intracellular calcium (Fig 1a). Acute intracellular calcium
responses were only ever observed when cells were co-
stimulated with 10 mM PIA (a pharmacological adenosine
agonist that inhibits the intracellular elevation of cAMP). PIA
alone did not elevate intracellular calcium levels in any of
the cells. Increases in intracellular calcium were typically
observed within the first 10 s of peptide (þPIA) addition to
the cells and responses returned to the original baseline
level approximately 30 to 60 s thereafter (Fig 1b and c).
Acute intracellular calcium responses were observed in
HaCaT human keratinocytes in response to a-MSH (from
1012 to 107 M), KPV (from 1013 to 107 M), KP-D-V (from
1015 to 107 M), and ACTH (from 1012 to 107 M). But
these cells very rarely responded to ACTH 1–17, with
positive responses observed only 10% of the time (Fig 1b,
Tables I and II). In contrast, acute intracellular calcium
responses were observed in normal human keratinocytes in
response to a-MSH (from 1011 to 108 M), KPV (from 1011
to 107 M), KP-D-V (from 1011 to 107 M), ACTH (from
1010 to 107 M), and ACTH 1–17 (from 1013 to 107 M)
(Fig 1c, Tables I and II). Particular sensitivity was observed
when stimulating the HaCaT keratinocytes with ACTH,
a-MSH, KPV, or KP-D-V, as positive responses were noted
when using peptides at very low concentrations (e.g.,
1015 M).
Intracellular free calcium responses to MSH and ACTH
peptides (þPIA) were also measured in HaCaT keratino-
cytes using fluorescence microscopy (Fig 2). The data
obtained using this method confirmed data collected above
by fluorimetry for acute responses to ACTH, a-MSH, KPV,
and KP-D-V (with and without PIA). Figure 2a shows an
acute intracellular calcium signal for a single keratinocyte
cell challenged with a-MSH (1012 Mþ 10 mM PIA). The
data illustrate visually the differences in intracellular calcium
levels using artificial coloring (overlaid to identify differences
in Fura-2 fluorescence). Thus, intracellular areas observed
as green corresponds to baseline levels (i.e., low calcium)
and red corresponds to areas of high regional calcium, with
yellow as intermediate. The kinetic profile and observed
fluorescent appearance did not differ with the peptide used.
Figure 1
Acute intracellular calcium responses measured in Fura2-AM-loaded human HaCaT keratinocytes and normal human keratinocytes
detected by optical fluorimetry: (a) HaCaT keratinocytes stimulated with ACTH, ACTH 1–17, a-MSH, KPV, or KP-D-V alone (109 M) did not lead to
acute increases in intracellular calcium; (b and c) co-stimulation of HaCaT (b) and normal human keratinocytes (c) with PIA (105 M) and MSH/ACTH
peptides lead to rapid and acute intracellular calcium release, returning to baseline values typically within 60 s. PIA was always added at the same
time as the peptides as indicated by position of individual vertical arrows. a-MSH, a-melanocyte-stimulating hormone; KPV, L-Lys-L-Pro-L-Val; KP-D-
V, L-Lys-L-Pro-D-Val; ACTH, adrenocorticotropin hormone; PIA, N6-(L-2-phenyl isopropyl) adenosine.
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Hence, a typical calcium response initiated by a-MSH was
observed within the first 4 s and appeared to originate in
both the cytoplasm and the nucleus at the same time.
Cytoplasmic fluorescence reached a maximum intensity
after 6 s and decreased rapidly thereafter. A strong
intracellular calcium response was also observed in the
nucleus. This too had a maximum intensity after about 6 s.
In contrast to the cytoplasm, the signal in the nucleus took a
longer period to abate, and even after 20 s was still
detectable. Indeed the overall intracellular calcium re-
sponse lasted for approximately 30 s before returning to
the baseline level equivalent to the fluorescence intensity of
the unstimulated cell. Therefore, the data obtained using the
microscopy technique broadly agree with data obtained by
fluorimetry. In addition it demonstrates that rapid calcium
release and recovery arises in the cytoplasm in contrast to
the nucleus, and that perinuclear regions appear to lack
calcium increases. This approach also showed that for
populations of cells in a microscope field of view (Fig 2b),
cells typically responded with calcium increases that
returned to resting levels after approximately 30 s (in
agreement with the single-cell studies). All cells were
observed to respond acutely, but differences were observed
between resting and peak intensities between cells. The
data suggest that resting levels of intracellular calcium differ
from keratinocyte to keratinocyte and that amplitudes of
individual responses also differ between cells.
Elevation of intracellular calcium in MC-1R/CHO-K1
cells Wild-type CHO-K1 cells (which do not express MC-
1 receptors) loaded with Fura-2 were challenged with
a-MSH, KPV, or KP-D-V (with and without 10 mM PIA). Cells
did not respond with an acute elevation of intracellular
calcium (Fig 3 and Table III), in contrast to responses
observed for keratinocytes above. But CHO-K1 cells that
were stably transfected with the MC-1 receptor responded
to co-stimulation of PIA (10 mM) and a-MSH, KPV, or KP-D-V
with a rapid elevation of intracellular calcium. Positive
responses were observed for peptides used at concentra-
tions varying from 1010 to 107 M and a return to the
baseline level arose in each case (Fig 3 and Table III). It was
of particular interest that the calcium response amplitude to
a-MSH (and the ‘‘superpotent’’ tripeptide KP-D-V) in the
MC-1R/CHO-K1 cells corresponded well with that seen for
the keratinocyte cells. In contrast, the amplitude observed
when cells were stimulated with KPV was somewhat
weaker (Fig 3).
Elevation of intracellular calcium and activation of
NF-jB We have reported previously that a-MSH, KPV,
and KP-D-V peptides inhibit TNF-a-stimulated activation of
the NF-kB transcription factor in keratinocyte cells (Mous-
tafa et al, 2002). This is one mechanism whereby the anti-
inflammatory properties of the MSH peptides are suggested
to arise. cAMP elevation is suggested as the mediating
intracellular signal, and data using receptor independent
agents (e.g., forskolin or IBMX) support this. HaCaT
keratinocytes were therefore analyzed for NF-kB activity
under conditions whereby the intracellular calcium levels
were elevated. In these experiments we used ionomycin at
106 M, as this compound in isolation elevates calcium
levels (as demonstrated in Fig 4) without compromising cell
viability. NF-kB activity was measured by immunolabelling
for the p65 subunit and determining the extent of nuclear
translocation (or retention) in the presence of the TNF-a
proinflammatory cytokine (as described previously in
Moustafa et al, 2002). Incubation of HaCaT keratinocytes
Table I. Acute intracellular calcium responses
Log (M)
Peptide
a-MSH KPV KP-D-V ACTH
ACTH
1–17
(a) In cultured human HaCaT keratinocytes
15 100% (3) 100% (3) 100% (3) 100% (3) N/D
14 100% (3) 100% (3) 100% (3) 100% (3) N/D
13 100% (3) 100% (3) 100% (3) 100% (3) N/D
12 100% (3) 100% (3) 100% (3) 100% (2) 0% (4)
11 100% (3) 100% (3) 100% (3) 100% (3) 0% (3)
10 100% (3) 100% (3) 100% (3) 100% (3) 0% (7)
9 100% (3) 100% (3) 100% (3) 100% (3) 10% (10)
8 100% (3) 100% (3) 100% (3) 100% (3) 10% (10)
7 100% (3) 100% (3) 100% (3) 100% (3) 0% (6)
(b) In normal human keratinocytes
13 N/D N/D N/D N/D 100% (3)
12 0% (3) 0% (3) 0% (3) 0% (3) 100% (3)
11 100% (3) 80% (5) 100% (2) N/D 100% (3)
10 N/D 100% (3) 100% (3) 100% (3) 67% (3)
9 100% (3) 100% (3) N/D 100% (3) 100% (3)
8 100% (5) 100% (4) 100% (3) 100% (3) N/D
7 N/D 100% (1) 100% (3) 100% (3) 100% (3)
Results are shown as a percentage of positive responses, with the
number of experimental repeats displayed in parentheses. Increases in
intracellular calcium were only observed when cells were co-stimulated
with peptide plus PIA (at 105 M).
a-MSH, a-melanocyte-stimulating hormone; KPV, L-Lys-L-Pro-L-Val;
KP-D-V, L-Lys-L-Pro-D-Val; ACTH, adrenocorticotropin hormone; N/D, not
detected.
Table II. A summary of the concentration ranges of MSH/ACTH
peptides that stimulate an acute intracellular calcium
response in human HaCaT keratinocytes and normal
human keratinocytes
Peptide HaCaT keratinocytes
Normal human
keratinocytes
a-MSHþPIA 1015–107 M 1011–108 M
KPVþPIA 1015–107 M 1011–107 M
KP-D-VþPIA 1015–107 M 1011–107 M
ACTH 1–17þPIA o10% positive responses 1013–107 M
ACTHþPIA 1015–107 M 1010–107 M
Peptide or PIA alone was ineffective at initiating an intracellular calcium
response in either cell type studied.
a-MSH, a-melanocyte-stimulating hormone; KPV, L-Lys-L-Pro-L-Val;
KP-D-V, L-Lys-L-Pro-D-Val; ACTH, adrenocorticotropin hormone.
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with ionomycin alone had no effect on NF-kB activity (Fig 4).
In contrast, a significant inhibition of TNF-a-stimulated
NF-kB activation was observed after a 60-min incubation
period (p¼0.026). We then selected an a-MSH concentra-
tion of 107 M that was previously reported not to inhibit
TNF-a-stimulated NF-kB activation in HaCaT keratinocytes
(Moustafa et al, 2002) and coincubated cells with TNF-a
(200U per mL), a-MSH (107 M), and ionomycin (106 M).
Under these conditions, we observed that inclusion of
ionomycin significantly enhanced the ability of a-MSH to
inhibit TNF-a-stimulated activation of NF-kB (p¼0.026;
Fig 4).
cAMP elevation by MSH/ACTH peptides The in vitro
culture conditions used to prepare normal and HaCaT
keratinocytes for intracellular calcium detection above were
adhered to for the measurement of cAMP elevation in
response to ACTH, a-MSH, KPV, and KP-D-V. We observed
that HaCaT keratinocytes and normal human keratinocytes
did not respond significantly to any of the peptides
investigated with an elevation of intracellular cAMP (Fig 5a
and b). In contrast the use of forskolin (at 105 and 104 M)
used as a positive control did cause an increase in cAMP
(Fig 5c). Figures 5a and b show the response of HaCaT
keratinocytes and normal human keratinocytes, respec-
tively, to a-MSH and KPV over a range of peptide
concentrations (from 1012 to 106 M).
MSH/ACTH peptide-stimulated dopa oxidase activity It
is widely reported that a-MSH stimulates dopa oxidase
activity in pigmentary cells, arising via an elevation of cAMP.
But as the data above suggest that a-MSH, the KPV
tripeptides, and ACTH were unable to elevate cAMP in
keratinoytes (Fig 5). We used a function assay to investigate
the comparative ability of these peptides to activate cAMP-
dependent dopa oxidase activity in B16F10C1 murine
melanoma cells. Cells were stimulated with a-MSH, KPV,
KP-D-V, ACTH 1–17, or ACTH for 24 h (with a-MSH being
used as a positive control, as it has previously been
reported to increase dopa oxidase activity in a concentra-
tion-dependent manner (Smith-Thomas et al, 1996)). a-MSH
was confirmed to activate dopa oxidase activity (with a
178%  12% increase over the control at 106 M, Fig 6a).
But we did not observe a significant increase in tyrosine
activity versus control with the tripeptides at any concen-
tration of peptide (from 1012 to 106 M; Fig 6a and b). It
was noted that a slight increase in enzyme activity arose at
106 M for both tripeptides, and ACTH 1-39 stimulated a
Figure 2
An acute intracellular calcium response in
Fura2-AM-loaded HaCaT keratinocytes de-
tected by fluorescence microscopy time-
lapse imaging. In this example, HaCaT cells
were co-stimulated with PIA (105 M) and
a-melanocyte-stimulating hormone (a-MSH)
(1012 M) at the point indicated by the vertical
arrow: (a) illustrates the complete cycle of
intracellular calcium release and recovery for
an individual cell; (b) intracellular calcium
signalling for a population of HaCaT cells in a
single field-of-view. Images were captured
every 2 s and artificially colored using graphical
software.
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slight increase in enzyme activity at 1011 and at 106 M
(Fig 6b).
Discussion
A number of studies report on a-MSH having a role in
cutaneous immunomodulation, including an ability to inhibit
TNF-a upregulation of surface ICAM-1 expression (pre-
requisite for T-lymphocyte binding) in melanocytes and
melanoma cells (Hedley et al, 1998; Morandini et al, 1998).
Kalden et al (1999) have reported that a-MSH inhibits the
expression of lipopolysaccharide, (LPS)-induced E-selectin,
and vascular cell adhesion molecule-1 (VCAM-1) on
endothelial cells (Kalden et al, 1999) and Brzoska et al
(1999) have reported that a-MSH inhibits the IL-1b activa-
tion of the NF-kB transcription factor in a human HaCaT
keratinocyte cell line (Brzoska et al, 1999). We have also
demonstrated that a-MSH inhibits the TNF-a-stimulated
activation of the NF-kB transcription factor in human ocular
and cutaneous melanocytes and melanoma cells (Haycock
et al, 1999a, b) and also in human keratinocyte cells
(Moustafa et al, 2002). The acute activation of NF-kB is
responsible for expression of several inflammatory and
immune system genes and can be activated by intracellular
peroxide species (Ghosh et al, 1998). We have also reported
that a-MSH inhibits GPx activity after stimulation with TNF-a
or hydrogen peroxide in human keratinocyte and melanoma
cells (Haycock et al, 2000). The above data highlight a
number of studies that support an important role of a-MSH
in acute protection of skin and endothelial cells to
proinflammatory cytokine action and oxidative stress.
In addition to the full-length a-MSH tridecapeptide
sequence having anti-inflammatory/immunomodulatory
action, other MSH-derived peptides are reported to have
activity. Significantly, the MSH 11–13 tripeptides (KPV
and KP-D-V) are thought to be the minimum sequence
necessary to convey anti-inflammatory signalling. The MSH
11–13 peptides have been shown to reduce picryl chloride
induced ear swelling in mice when administered by
intracranial injection (Hiltz and Lipton, 1989; Hiltz et al,
1991); furthermore, they are also able to inhibit TNF-a-
stimulated activation of NF-kB in normal human keratino-
cytes and in a keratinocyte cell line (Moustafa et al, 2002)
and inhibit GPx activity in keratinocyte and melanoma lines
(Haycock et al, 2000). A study by Mandrika et al (2001)
however, showed that whereas MSH 11–13 could inhibit the
LPS/g-interferon activation of NF-kB in murine monocytes/
macrophage RAW 264.7 cells, the tripeptides did not act via
the same receptor signalling pathway as a-MSH. Further-
more, receptor-binding studies using KPV conjugated to
melphalan report no significant binding to the a-MSH
receptor (Morandini et al, 1994). It is therefore not known
whether the MSH 11–13 peptides signal via an MSH
receptor or via an alternative route.
a-MSH signalling arises the G-protein linked melanocor-
tin receptors. Five receptors have been cloned to date (MC-
1R–MC-5R) (Chhajlani and Wikberg, 1992; Mountjoy et al,
1992), with a-MSH having highest affinity for MC-1R. This
receptor is expressed on a number of cells in the skin
including melanocytes (Mountjoy et al, 1992), keratinocytes
(Chakraborty et al, 1996), and fibroblasts (Bo¨hm et al, 1999).
Recent studies have also reported expression of MC-2R on
human keratinocytes (Moustafa et al, 2002). The melano-
cortin receptors signal via activation of adenylate cyclase
and elevation of cAMP; however, a-MSH has been shown to
activate signalling pathways other than cAMP including
activation of PKC (Buffey et al, 1992) and elevation of
intracellular calcium (MacNeil et al, 1990) in B16 mouse
Figure 3
Acute intracellular calcium responses in Fura2-AM-loaded wild-
type CHO-K1 cells and CHO-K1 cells stably transfected with the
MC-1 receptor, detected by optical fluorimetry. No acute increases
in intracellular calcium were observed for wild-type CHO-K1 cells.
CHO-K1 cells transfected with the MC-1 receptor demonstrate acute
increases in intracellular calcium responses when co-stimulated with
a-MSH, KPV, KP-D-V, and PIA at 105 M. PIA was always added at the
same time as the peptides as indicated by position of individual vertical
arrows. In this illustration all peptides were used at 108 M. a-MSH,
a-melanocyte-stimulating hormone; KPV, L-Lys-L-Pro-L-Val; KP-D-V,
L-Lys-L-Pro-D-Val; ACTH, adrenocorticotropin hormone; PIA, N6-(L-2-
phenyl isopropyl) adenosine.
Table III. Acute intracellular calcium responses
(Log M)  PIA
Peptide
a-MSH KP-D-V KPV
(a) In untransfected CHO-K1 cells
8 without PIA 0% (5) 0% (5) 0% (5)
8þPIA 0% (15) 0% (12) 0% (15)
16þPIA 0% (5) 0% (5) 0% (5)
(b) In MC-1R-transfected CHO-K1 cells
11 0% (3) N/D 0% (1)
10 75% (4) 0% (4) 75% (4)
9 8% (12) 33% (6) N/D
8 100% (2) 19% (16) 27% (15)
7 45% (11) 25% (4) N/D
6 N/D 0% (5) 0% (2)
Increases in intracellular calcium were only observed when cells were
co-stimulated with peptide plus PIA. Results are shown as a percentage
of positive responses, with the number of experimental repeats displayed
in parentheses.
a-MSH, a-melanocyte-stimulating hormone; MC-1R, melanocortin-1
receptor ACTH, adrenocorticotropin hormone; N/D, not detected.
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melanoma cells. a-MSH is also reported to act via the p38
MAP kinase pathway promoting melanogenesis and inhibit-
ing growth in melanoma cells (Smalley and Eisen, 2000) and
also activation of the STAT1 transcription factor in B-
lymphocytes via the MC-5 receptor (Buggy, 1998). Of
particular interest is the discovery that two pathways may
emanate from a single type of receptor, and that a one
pathway signal by inhibiting the other. For example, in a
study by Konda et al (1994) using Chinese hamster ovary
cells transfected with the MC-3 receptor it was shown that
a-MSH could increase intracellular calcium, but only if
the cAMP/protein kinase A pathway was inhibited. Data
suggest that if a predominant cAMP pathway is inhibited
then an intracellular calcium pathway can be detected from
the same receptor.
We have therefore extended our previous studies on the
anti-inflammatory mechanism of a-MSH, the MSH tripep-
tides, and ACTH peptides in NHK and HaCaT keratinocyte
cells to investigate whether the ‘‘cross-talking’’ between
cAMP and calcium signalling pathways exists in keratino-
cytes. Neither of the keratinocyte types studied responded
to a-MSH, KPV, KP-D-V, or ACTH peptides with a significant
Figure 4
The effect of elevating intracellular calcium on the cytokine (tumor
necrosis factor (TNF-a))-stimulated activation of nuclear factor-jB
(NF-jB) in HaCaT keratinocytes. (a) NF-kB was measured according
to p65 immunolabelling and assessment of intracellular localization.
Light bars¼no ionomycin, dark bars¼ ionomycin present at 106 M.
Ionomycin had no effect on control-unstimulated levels of NFkB
activation. Cells stimulated with 200 U per mL of TNF-a showed NF-
kB activation, which was inhibited by ionomycin compared to TNF-a
alone (p¼0.026). a-MSH (at 107 M) did not inhibit TNF-a-stimulated
NF-kB activity but co-stimulation with ionomycin (106 M) and
a-melanocyte-stimulating hormone (a-MSH) (107) significantly inhib-
ited NF-kB (p¼ 0.005) compared to TNF-a and a-MSH alone
(p¼ 0.026) and TNF-a alone. (b) Intracellular calcium response of
Fura2-AM-loaded HaCaT keratinocytes to addition of ionomycin (at
106 M, used for NF-kB measurement) detected by optical fluorimetry.
NS, not significant; , po0.05; , po0.01; , po0.001.
Figure5
cAMP elevation measured in HaCaT keratinocytes and normal
human keratinocytes. (a) HaCaT keratinocytes and (b) normal human
keratinocytes were incubated with a-MSH (’) or KPV (m) from 1012 to
106 M for 20 min. Cell extracts were prepared and cAMP measured
according to Michelangeli et al (1994). (c) cAMP elevation measured in
HaCaT keratinocytes in response to a-MSH, KPV, KP-D-V, and ACTH at
108 and 106 M for 24 h. Forskolin was used as a positive control at
104 and 105 M. a-MSH, a-melanocyte-stimulating hormone; KPV,
L-Lys-L-Pro-L-Val; KP-D-V, L-Lys-L-Pro-D-Val; ACTH, adrenocorticotro-
pin hormone.
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elevation in cAMP; however, both cell types demonstrated
cAMP elevation in response to the receptor-independent
agent forskolin. The same peptides were not able to elevate
intracellular calcium levels when introduced alone to NHK or
HaCaT keratinocytes in culture. But a strong acute release
of calcium was detected when each peptide was intro-
duced together with PIA. (PIA is a very specific adenosine
agonist that inhibits the activation of adenylate cyclase and
elevation of cAMP). We have previously confirmed this
approach in JP09 cells transfected with the G-protein linked
thyroid-stimulating hormone (TSH) receptor, demonstrating
a calcium response to TSH when using PIA to inhibit the
TSH-stimulated elevation of cAMP (Metcalfe et al, 1998).
We therefore used the same approach in this study and
observed acute intracellular calcium signalling in keratino-
cyte cells stimulated with a-MSH, KPV, KP-D-V, ACTH
1—39, and ACTH 1–17. The response of the HaCaT keratino-
cytes was of particular interest, as the MSH peptides
signalled at concentrations as low as 1015 M. This is
unusual as most kinetic receptor binding and signalling
responses between a-MSH and MC-1R tend to cease at
a-MSH concentrations approximating 1012 M. It is there-
fore possible that the HaCaT keratinocytes express a high-
affinity receptor not present on the normal cell type. It is
interesting to note that low functional a-MSH concentra-
tions have previously been reported including levels of
1013 M on the production of IL-10 in monocyte cells
(Bhardwaj et al, 1996) and 1016 M on NF-kB activation in
endothelial cells (Kalden et al, 1998).
Normal human keratinocytes immunolabel for both
MC-1R and MC-2R (Moustafa et al, 2002), whereas HaCaT
keratinocytes only immunolabel positively for MC-1R (with
weak immunolabelling for MC-2R). HaCaT keratinocytes
have also demonstrated an ability to bind a-MSH. The
intracellular calcium responses observed in NHK and
HaCaT cells in response to ACTH probably arise via an
MC-1R route in HaCaT keratinocytes and through MC-1R
or MC-2R in NHK cells. ACTH 1-17 is found in high
concentrations in the skin (Chakraborty et al, 1996;
Wakamatsu et al, 1997) and is known to act through
MC-1R to raise intracellular cAMP levels (Tsatmali et al,
1999). ACTH 1-17 also raises inositol trisphosphate (IP3)
levels in MC-1R-transfected HEK293 cells (Tsatmali et al,
1999), whereas a-MSH does not. It is not known if this
peptide acts through MC-2R, but present data on a lack of a
calcium signal in HaCaT keratinocytes versus NHK cells
would suggest this as a possible mechanism.
The unresponsiveness of NHK and HaCaT keratinocytes
to a-MSH, KPV, KP-D-V, and ACTH on cAMP elevation does
not entirely correlate with the requirement of PIA to reveal
acute intracellular calcium signals, as it infers that a cAMP
signal is present. We strictly followed an experimental
procedure for cAMP measurement that corresponded with
positive calcium responses in this study and MSH anti-
inflammatory peptide responses reported in previous
studies (Haycock et al, 1999a, b, 2000; Moustafa et al,
2002). Therefore, the data on cAMP correlate with other
studies reporting on MSH function using a consistent
experimental approach. Experimental approaches that
avoid inadvertent elevation of cAMP are reported in the
literature (e.g., Abdel-Malek et al, 1995) and it is therefore
possible that serum deprivation in the culture medium or an
ability to culture NHK cells on a collagen-free substrate
would identify cAMP elevation in response to the peptides
studied. It is entirely possible that the MSH peptides either
have a small but significant action on elevating cAMP
(sufficient to inhibit an intracellular calcium response, but
too small to measure), or that the MC-1 receptor produces.
The role of the MC-1 receptor was examined in CHO
cells as the mechanism for conducting intracellular calcium
signalling by a-MSH, KPV, and KP-D-V. Wild-type CHO cells
did not respond with an increase in intracellular calcium
when stimulated with these peptides, either in the presence
or absence of PIA. But when cells were transfected with the
MC-1R a high percentage of HaCaT keratinocyte experi-
ments responded to a-MSH/PIA co-stimulation with an
intracellular calcium release. A lesser number of experi-
ments responded with the MSH tripeptide KP-D-V, with the
fewest number responding to the KPV peptide; however,
positive calcium responses were observed for both KP-D-V
and KPV tripeptides studied, compared to completely
negative responses seen in the wild-type cells. This data
Figure 6
Cultured B16C1F10 pigmentary murine melanoma cells were
incubated with: (a) a-MSH (’), KPV (m) or KP-D-V (~) and (b) ACTH
(m) or ACTH 1—17 (  ) for 24 h and extracts measured for dopa
oxidase activity. a-MSH, a-melanocyte-stimulating hormone; KPV,
L-Lys-L-Pro-L-Val; KP-D-V, L-Lys-L-Pro-D-Val; ACTH, adrenocorticotro-
pin hormone.
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therefore support a role of the MC-1 receptor in the
intracellular calcium signalling pathway, and also suggest
a potential for the KPV/KP-D-V tripeptides to signal via the
MC-1 receptor. It is, therefore, most likely that calcium
signalling in keratinocytes arises by MC-1R, as this receptor
is known to be expressed in keratinocytes and a-MSH has
highest affinity for the MC-1R, compared with MC-2–5R.
Our own group and others have published on the role of
the MSH/ACTH peptides on inhibiting cytokine-stimulated
NF-kB activity (e.g., Haycock et al, 1999a, b) in a number of
different cell types. This is one mechanism whereby a-MSH
can act as an immunomodulatory molecule. The data also
support a role of the cAMP pathway on inhibiting NF-kB
activation. As we have identified an ability of MSH and
ACTH peptides to stimulate intracellular calcium levels in
keratinocytes, we therefore decided to study to what extent
the elevation of intracellular calcium would have on TNF-a-
stimulated NF-kB activity. Elevation of intracellular calcium
using ionomycin at 106 M in HaCaT cells demonstrated an
ability to raise calcium. This had no effect on the resting
level of NF-kB activity in unstimulated HaCaT cells, but
served to moderately inhibit the TNF-a-stimulated activation
of NF-kB (identified as significant). In addition, an elevation
of intracellular calcium significantly enhanced the ability of
a-MSH to inhibit TNF-a-stimulated activation of NF-kB.
Therefore, the data support a hypothesis that a-MSH can
inhibit inflammatory cytokine activation of NF-kB by an
elevation of the calcium-signalling pathway. Hence, the anti-
inflammatory role of a-MSH can arise via elevation of cAMP
or via intracellular calcium. The source of acute calcium
release clearly originates from intracellular sources, based
on Fura-2 microscopy revealing that deeper cytoplasmic
areas respond prior to plasma membrane-associated
regions. It is likely that this involves a phospholipase
C/inositol 1,4, 5-trisphosphate mechanism facilitating re-
lease from the endoplamsic reticulum; however, a more
detailed study of the exact calcium mechanism would be
required to confirm this.
Activation of the cAMP-dependent pigmentary enzyme
dopa oxidase in B16F10C1 murine melanoma cells demon-
strated a-MSH to have concentration-dependent agonist
activity, with a maximum activity observed at 106 M. In
contrast, the KPV and KP-D-V peptides were ineffective at
stimulating dopa oxidase activity. A slight increase in
enzyme activity was observed at 106M, but this was not
significant. The results are consistent with an inability of the
tripeptides to elicit an elevation of cAMP in keratinocyte
cells, and it is possible that the tripeptides may act via a
different pathway from the MC-1 receptor to that of a-MSH.
But as use of the tripeptides are generating commercial
interest as anti-inflammatory agents (e.g., Lyproval, Gen-
zyme Inc., California), it may be of considerable interest that
any anti-inflammatory biology conveyed by these peptides
is less likely to be associated with a pigmentary response,
in contrast to the well-reported pigmentary properties of a-MSH.
The role of ACTH and related peptides in human skin
tissue are also suggested to be part of the stress response
(Slominsky et al, 2000a, b) and ACTH and truncated
fragments (ACTH 1–17) have been isolated from skin tissue
(Wakamatsu et al, 1997; Chakraborty et al, 1996). ACTH is
known to signal strongly through the MC-2 receptor (Eberle,
1988) and investigators have reported that ACTH is as
effective as a-MSH in stimulating melanogenesis in human
melanocytes in culture (Hunt et al, 1994). ACTH has a similar
binding affinity to MC-1R as a-MSH (Chhajlani and Wikberg
1992), whereas the truncated ACTH 1–17 peptide has a
very high affinity for MC-1 receptor (Tsatmali et al, 1999),
stimulating the adenylate cyclase enzyme (Wakamatsu et al,
1997), elevating cAMP and IP3 (Tsatmali et al, 1999).
Whether ACTH 1–17 binds and signals through the MC-2
receptor is not known at present.
In summary, the POMC relates peptides a-MSH, KPV,
KP-D-V, ACTH, and ACTH 1–17 elevated intracellular
calcium levels in NHK and HaCaT keratinoctyes, but only
when the cAMP pathway was inhibited pharmacologically.
This supports the hypothesis described for other cells of
‘‘cross-talk’’ from a G-protein-linked receptor. The MSH
peptides were shown to act specifically via the MC-1
receptor on causing a calcium signal, using MC-1R-
transfected CHO-K1 cells. Elevation of intracellular calcium
was also found to inhibit the TNF-a cytokine-stimulated
activation of the NF-kB transcription factor. It also en-
hanced the response of a-MSH to inhibit under these
conditions. Unexpectedly, keratinocyte cells did not in-
crease intracellular cAMP levels in response to any of the
MSH/ACTH peptides, but it is possible that small undetect-
able levels exist sufficient to inhibit calcium signalling. In
conclusion, MSH/ACTH peptides can stimulate calcium
signalling in keratinocyte cells when in the absence of cAMP
elevation, and the function of this signal appears to be
similar to that of cAMP at inhibiting NF-kB activation.
Materials and Methods
Peptide dilutions ACTH, ACTH 1-17, a-MSH, and MSH11–13
(KPV and KP-D-V) (purchased from Bachem, Bubendorf, Switzer-
land) were prepared as a 100 mM stock solution in sterile double-
distilled water, divided into 50 or 100 mL aliquots and stored at
201C until required. All peptides were serially diluted immediately
prior to experimentation.
Normal human keratinocytes were obtained from abdomnio-
plasty operations that were surplus to requirement under patient
consent via collaborating plastic surgeons, via local ethically
approved guidelines. (NH Trust, Sheffield, UK).
Normal human keratinocyte and HaCaT keratinocyte culture
The HaCaT human keratinocyte cell line was kindly supplied by
Professor N.E. Fusenig (Institute of Biochemistry, German Cancer
Research Centre, Heildelberg, Germany) (Boukamp et al, 1988).
Cells were cultured in Dulbecco’s Modified Eagles medium (Sigma-
Aldrich, Poole, Dorset, UK) with 5% (vol/vol) fetal calf serum (FCS)
(Labtech, East Sussex, UK), 2mM L-glutamine, penicillin/strepto-
mycin (100 IU per mL/100 mg per mL), and fungizone (0.625 mg
per mL) (Gibco, Paisley, UK) and were grown in a humidified
atmosphere (95% air, 5% CO2 at 371C). Human primary keratino-
cytes were established in culture after isolation from full thickness
skin obtained from abdominoplasty and breast reduction opera-
tions (following local ethical committee guidelines) as described
previously (Goberdhan et al, 1997). Briefly, keratinocytes were
harvested from skin pre-treated with a trypsin/EDTA solution
overnight and then cultured in Green’s medium (10% vol/vol
FCS) in T75 flasks coated with rat tail collagen (0.02 mg per cm2).
Second passage normal human keratinocytes were used for
intracellular calcium and cAMP measurement (described below)
and were from the same patient, whereas HaCaT keratinocytes
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were used at passages 35–60 for experimentation. All experiments
were repeated three times unless specified elsewhere.
B16F10C1 mouse melanoma culture B16F10C1 mouse mela-
noma cells were cultured in Eagle’s Minimum Essential Medium
(Sigma-Aldrich with 10% (vol/vol) FCS (Labtech), 2 mM
L-glutamine, penicillin/streptomycin (100 IU per mL/100 mg per
mL), fungizone (0.625 mg per mL) (Gibco), 1% (vol/vol) non-
essential amino acids, 1% (vol/vol) vitamin concentrate, 2.5% (vol/
vol) sodium bicarbonate (7.5% solution), and 1% (vol/vol) sodium
pyruvate (Sigma–Aldrich). B16F10C1 cells were used at passages
15–40 for experimentation.
Generation of a CHO-K1 cell line with stable expression of
MC-1R A stable cell line expressing functional MC-1R was
isolated by transfecting CHO-K1 cells with vector pRc/CMV
(Invitrogen, Groningen, The Netherlands) carrying MC-1 cDNA (a
gift from Professor J.E.S. Wikberg, Uppsala University, Sweden).
Briefly, cells were plated in 100-mm dishes in Ham’s F12 medium
containing 10% FCS, 2 mM L-glutamine, 50U per mL penicillin G,
and 50 mg per mL streptomycin (all from Invitrogen). After growth
to approximately 70% confluence, the cells were transfected with
15 mg of pRc/CMV/MC-1 DNA using Tfx-50 Reagent (Promega,
Southampton, UK), according to the manufacturer’s protocol.
Following 48 h incubation, the transfected cells were re-plated at
limiting dilutions in growth medium containing 400 mg per mL
geneticin (Invitrogen). Colonies derived from single cells were
isolated, expanded, and screened in the calcium-response assay.
Intracellular calcium by Fura2-AM ﬂuorimetry HaCaT keratino-
cytes and normal human keratinocytes were cultured on glass
coverslips (22 mm  12 mm  0.17 mm) and collagen type I
coated glass coverslips, respectively. CHO wild-type and cells
stably transfected with the MC-1R were cultured on glass
coverslips. All cells were seeded at a density of 1  106 per well
(6-well plate) and cultured for 2–3 d, or until approximately 80%
confluent. For experimentation, cells were loaded with 0.02 mM
Fura2-AM at 371C in the dark for 15–30 min in a balanced salt
solution (BSS; 135 mM NaCl, 4.5 mM KCl, 1.5 mM CaCl2, 0.5 mM
MgCl2, 5.6 mM glucose, and 10 mM Hepes, pH 7.4). All chemicals
were obtained from BDH Merck Ltd (Leicester, UK) and were of
analytical grade unless otherwise stated. Fura2-AM-loaded cells
were washed twice with BSS to remove extracellular unloaded
fluorophore. Acute changes in intracellular free calcium were mea-
sured in real time using a Kontron SFM25 fluorimeter (lex¼ 335
nm, lem¼ 490 nm) linked to a graphical plotter, in response to cells
challenged individually with a combination of MSH and ACTH
peptides used at concentrations from 1015 to 106 M or
ionomycin (106 M). Cells were also challenged with peptides plus
an adenosine derivative N6-(L-2-phenylisopropyl) adenosine (PIA,
Sigma, UK) as described previously (Metcalfe et al, 1998).
Intracellular calcium by ﬂuorescence microscopy Intracellular
free calcium was measured in HaCaT keratinocytes loaded
with Fura2-AM in response to MSH/ACTH peptides as above
(1015–106 M  PIA 105 M) using a Leica DM-IRB inverted
fluorescent microscope. HaCaT keratinocytes were grown on 25
mm diameter circular glass coverslips as above. Fura2-AM-loaded
cells were observed using epifluorescent illumination and intracel-
lular free calcium measured every 2 s using pinkel filters (lex¼ 340
nm, mem¼ 510 nm (Glen Spectra, Stanmore, Middlesex, UK)).
Digital images were captured using an integrated camera
(Hamamatsu Orca) and processed with graphical software for
image analysis (Openlab v 3.0, Improvision, Coventry, UK).
Changes in fluorescence intensity were ‘‘color-fitted’’ with a
‘‘Rainbow’’ overlay scheme derived from raw data captured in
grayscale (thousands of grays). Visual intensity changes were
derived by ratio plotting all data points with the basal signal
intensity measured in Fura2-loaded unstimulated cells (i.e., in the
absence of intracellular free calcium).
Activation of NF-jB NF-kB activation was measured in cultured
HaCaT keratinocyte cells by immunolabelling for the intracellular
position of the p65 transriptionally active subunit, according to
details described previously (Moustafa et al, 2002). This technique
is found to correlate with alternative methods for assessment of
NF-kB activity (e.g., electrophoretic mobility shift assay). Briefly,
cells were cultured until 60% confluence and stimulated with
ionomycin (106 M) (Sigma-Aldrich) or a-MSH (107 M) alone or in
combination for 15 min, followed by addition of TNF-a (200 U per
mL) (Roche Diagnostics Ltd, East Sussex, UK) for a further 60 min.
Experiments were stopped by addition of 4% (wt/vol) paraformal-
dehyde (BDH/Merck, Poole, Dorset, UK) in phosphate-buffered
saline (PBS). Cells were permeablized (0.1% (vol/vol) Triton  100
in PBS) (BDH/Merck) and neutralized (200 mL 50 mM ammonium
chloride (in PBS) (BDH/Merck). Cells were washed three times in
PBS between treatments. Unreactive binding sites were blocked
with 5% (wt/vol) dried milk powder (in PBS) for 30 min. Cells were
then incubated with the primary anti-NF-kB/p65 (C-20) goat
polyclonal IgG antibody (sc-109, Santa Cruz Biotechnology,
California) for 1 h at room temperature and pressure (1:100 (vol/
vol) in PBS). Cells were washed with PBS (  3) then incubated
with biotinylated anti-goat IgG antibody (BA-5000, Vector Labora-
tories Inc., California, 1:1000 vol/vol in PBS) for 1 h at RTP, washed
with PBS (  3), followed by incubation with fluorescein strepta-
vidin (SA-5001, Vector) (1:100 vol/vol in PBS) and 300 nM DAPI
(Sigma-Aldrich) for 30 min.
NF-kB/p65 images were captured using an ImageXpress 5000A
automated cellular imaging and analysis system (Axon Instru-
ments, California). DAPI fluorescence was used for identification of
the nuclei and fluriosothiocvanate (FITC) fluorescence for NF-kB
cellular position. The boundary between the cell nucleus and
cytoplasm was circumscribed by ImageXpress analysis software
(ImageXpress Console 1.0) and the NF-kB in each individual cell
was considered activated if the intensity of the nuclei FITC-labelled
NF-kB was greater than that of the cytoplasmic FITC-labelled
NF-kB.
Measurement of cAMP Intracellular cAMP accumulation was
determined using tritiated (H3) adenine labelling of the nucleotide
pool. Cells were exposed to MSH/ACTH peptides at 371C for
15 min (1012–106 M) as previously described (Michelangeli et al,
1994) except that tritiated cAMP was separated from other
nucleotides using neutral alumina chromatography alone rather
than a combination of ion exchange chromatography and neutral
alumina chromatography as used by Michelangeli et al (1994). All
determinations were performed in triplicate.
Dopa oxidase activity Dopa oxidase activity was measured using
B16F10C1 mouse melanoma cells, as these cells are known to
respond to a-MSH with an increase in dopa oxidase activity (Smith
Thomas et al, 1996). Dopa oxidase will specifically oxidize L-Dopa
to dopaquinone, with an increase in optical density detectable at
490 nm. Cells were seeded in 96-well plates at 1  104 cells per
well and cultured for 24 h (to approximately 60% confluence). Cells
were incubated with MSH or ACTH peptides using a concentration
range of 1012 to 106 M for a period of 24 h. After peptide
incubation, cells were washed three times with PBS and lyzed by
addition of 0.1% (vol/vol) Tween 20 in Na2HPO4/NaH2PO4 buffer
(0.1 M, pH 6.8) (BDH/Merck). Lysis was enhanced by a cyclical
freeze thawing (801C, 30 min; RTP, 20 min; 371C, 30 min). The
dopa oxidase substrate L-Dopa (10 mM) (Sigma-Aldrich) was then
added to whole cell lyzates and optical density measurements (at
490 nm) were taken at 30-min intervals. Dopa oxidase activity was
calculated by the change in absorbance/well/minute at 490 nm.
Statistics Student’s unpaired one-way t test was used to compare
data between control and test samples.
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